138 related articles for article (PubMed ID: 19306511)
21. Continued pemetrexed and platin-based chemotherapy in patients with malignant pleural mesothelioma (MPM): value of 18F-FDG-PET/CT.
Schaefer NG; Veit-Haibach P; Soyka JD; Steinert HC; Stahel RA
Eur J Radiol; 2012 Jan; 81(1):e19-25. PubMed ID: 21129871
[TBL] [Abstract][Full Text] [Related]
22. Metabolic imaging of malignant pleural mesothelioma with fluorodeoxyglucose positron emission tomography.
Bénard F; Sterman D; Smith RJ; Kaiser LR; Albelda SM; Alavi A
Chest; 1998 Sep; 114(3):713-22. PubMed ID: 9743156
[TBL] [Abstract][Full Text] [Related]
23. Relationship between 18 FDG PET-CT findings and the survival of 177 patients with malignant pleural mesothelioma.
Abakay A; Komek H; Abakay O; Palanci Y; Ekici F; Tekbas G; Tanrikulu AC
Eur Rev Med Pharmacol Sci; 2013 May; 17(9):1233-41. PubMed ID: 23690193
[TBL] [Abstract][Full Text] [Related]
24. The role of PET in the surgical management of malignant pleural mesothelioma.
Flores RM
Lung Cancer; 2005 Jul; 49 Suppl 1():S27-32. PubMed ID: 15950796
[TBL] [Abstract][Full Text] [Related]
25. The value of dual time point (18)F-FDG PET imaging for the differentiation between malignant and benign lesions.
Lan XL; Zhang YX; Wu ZJ; Jia Q; Wei H; Gao ZR
Clin Radiol; 2008 Jul; 63(7):756-64. PubMed ID: 18555033
[TBL] [Abstract][Full Text] [Related]
26. Prognostic value of 18F-FDG PET/CT in patients with malignant pleural mesothelioma.
Lee ST; Ghanem M; Herbertson RA; Berlangieri SU; Byrne AJ; Tabone K; Mitchell P; Knight SR; Feigen M; Scott AM
Mol Imaging Biol; 2009; 11(6):473-9. PubMed ID: 19330385
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of delayed 18F-FDG PET in differential diagnosis for malignant soft-tissue tumors.
Hamada K; Tomita Y; Ueda T; Enomoto K; Kakunaga S; Myoui A; Higuchi I; Yoshikawa H; Hatazawa J
Ann Nucl Med; 2006 Dec; 20(10):671-5. PubMed ID: 17385305
[TBL] [Abstract][Full Text] [Related]
28. A comparative study of F-18 FDG PET and 201Tl scintigraphy for detection of primary malignant bone and soft-tissue tumors.
Yamamoto Y; Kawaguchi Y; Kawase Y; Maeda Y; Nishiyama Y
Clin Nucl Med; 2011 Apr; 36(4):290-4. PubMed ID: 21368603
[TBL] [Abstract][Full Text] [Related]
29. Normal variants of bowel FDG uptake in dual-time-point PET/CT imaging.
Toriihara A; Yoshida K; Umehara I; Shibuya H
Ann Nucl Med; 2011 Apr; 25(3):173-8. PubMed ID: 21088936
[TBL] [Abstract][Full Text] [Related]
30. Accuracy of PET for diagnosis of solid pulmonary lesions with 18F-FDG uptake below the standardized uptake value of 2.5.
Hashimoto Y; Tsujikawa T; Kondo C; Maki M; Momose M; Nagai A; Ohnuki T; Nishikawa T; Kusakabe K
J Nucl Med; 2006 Mar; 47(3):426-31. PubMed ID: 16513611
[TBL] [Abstract][Full Text] [Related]
31. Monitoring of chemotherapy response in malignant pleural mesothelioma using fluorodeoxyglucose positron emission tomography.
Kimura T; Koyama K; Kudoh S; Kawabe J; Yoshimura N; Mitsuoka S; Shiomi S; Hirata K
Intern Med; 2008; 47(23):2053-6. PubMed ID: 19043260
[TBL] [Abstract][Full Text] [Related]
32. Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesions.
Okada M; Shimono T; Komeya Y; Ando R; Kagawa Y; Katsube T; Kuwabara M; Yagyu Y; Kumano S; Imaoka I; Tsuchiya N; Ashikaga R; Hosono M; Murakami T
Ann Nucl Med; 2009 Jun; 23(4):349-54. PubMed ID: 19340526
[TBL] [Abstract][Full Text] [Related]
33. Early response evaluation in malignant pleural mesothelioma by positron emission tomography with [18F]fluorodeoxyglucose.
Ceresoli GL; Chiti A; Zucali PA; Rodari M; Lutman RF; Salamina S; Incarbone M; Alloisio M; Santoro A
J Clin Oncol; 2006 Oct; 24(28):4587-93. PubMed ID: 17008700
[TBL] [Abstract][Full Text] [Related]
34. 18-FDG positron emission tomography in the evaluation of malignant pleural diseases - a pilot study.
Carretta A; Landoni C; Melloni G; Ceresoli GL; Compierchio A; Fazio F; Zannini P
Eur J Cardiothorac Surg; 2000 Apr; 17(4):377-83. PubMed ID: 10773558
[TBL] [Abstract][Full Text] [Related]
35. 18F-fluoro-2-deoxy-D-glucose positron emission tomography and positron emission tomography/computed tomography imaging of malignant pleural mesothelioma.
Subramaniam RM; Wilcox B; Aubry MC; Jett J; Peller PJ
J Med Imaging Radiat Oncol; 2009 Apr; 53(2):160-9; quiz 170. PubMed ID: 19527361
[TBL] [Abstract][Full Text] [Related]
36. Integrated positron emission tomography-computed tomography does not accurately stage intrathoracic disease of patients undergoing trimodality therapy for malignant pleural mesothelioma.
Pilling J; Dartnell JA; Lang-Lazdunski L
Thorac Cardiovasc Surg; 2010 Jun; 58(4):215-9. PubMed ID: 20514576
[TBL] [Abstract][Full Text] [Related]
37. Prospective evaluation of solitary thyroid nodule on 18F-FDG PET/CT and high-resolution ultrasonography.
D'Souza MM; Marwaha RK; Sharma R; Jaimini A; Thomas S; Singh D; Jain M; Bhalla PJ; Tripathi M; Tiwari A; Mishra A; Mondal A; Tripathi RP
Ann Nucl Med; 2010 Jun; 24(5):345-55. PubMed ID: 20373060
[TBL] [Abstract][Full Text] [Related]
38. Is 18F-FDG PET/CT capable of differential diagnosis from tuberculous pleurisy from malignant mesothelioma?
Özmen Ö; Tatci E; Demiröz ŞM; Tazeler Z; Demirağ F
Nucl Med Commun; 2021 Jun; 42(6):672-677. PubMed ID: 33625184
[TBL] [Abstract][Full Text] [Related]
39. Malignant pleural mesothelioma: initial experience in integrated (18)F-FDG PET/MR imaging.
Schaarschmidt BM; Sawicki LM; Gomez B; Grueneisen J; Hoiczyk M; Heusch P; Buchbender C
Clin Imaging; 2016; 40(5):956-60. PubMed ID: 27232931
[TBL] [Abstract][Full Text] [Related]
40. Integrated FDG PET-CT imaging improves staging in malignant pleural mesothelioma.
Krüger S; Pauls S; Mottaghy FM; Buck AK; Schelzig H; Hombach V; Reske SN
Nuklearmedizin; 2007; 46(6):239-43. PubMed ID: 18084678
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
